Celsion (CLSN) Reports Q2 Loss of $0.46

Celsion (NASDAQ: CLSN) reported Q2 EPS of ($0.46), versus $0.00 reported last year.

“Celsion continues to make significant progress with our two ongoing clinical development programs for ThermoDox® and GEN-1. We expect to complete enrollment in our 550-patient global, pivotal Phase III OPTIMA Study in primary liver cancer and initiate patient enrollment in our 130-patient Phase I/II randomized OVATION II Study in newly diagnosed patients with ovarian cancer during the third quarter,” said Michael H. Tardugno, Celsion's chairman, president and chief executive officer. “We have a strong balance sheet and are well positioned financially to continue to advance these key programs, with several important announcements for both of our clinical programs expected over the next six to 12 months, including the final progression-free survival data from our OVATION I Phase IB clinical trial of GEN-1 and the first pre-planned interim analysis of the ThermoDox® Phase III OPTIMA Study."

For earnings history and earnings-related data on Celsion (CLSN) click here.

You May Also Be Interested In

• Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
• CPS Technologies (CPSH) Reports In-Line Q3 EPS
• McDonald's posts better-than-expected third-quarter comparable sales